Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity.

Literature DB >> 35752885

Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity.

Aditya Rali, Ye Huang, Steven Yeh.

Abstract

Entities: Chemical

Mesh：

Year: 2022 PMID： 35752885 PMCID： PMC9245155 DOI： 10.1097/IIO.0000000000000434

Source DB: PubMed Journal: Int Ophthalmol Clin ISSN： 0020-8167

Keyword Cloud
References

× No keyword cloud information.

77 in total

1. Choroidal Neovascularization in Multifocal Choroiditis after Dabrafenib and Trametinib.

Authors: Giorgia C Albertini; Eleonora Corbelli; Maurizio Battaglia Parodi; Francesco Bandello
Journal: Eur J Ophthalmol Date: 2017-11-08 Impact factor: 2.597

Review 2. T cell exhaustion.

Authors: E John Wherry
Journal: Nat Immunol Date: 2011-06 Impact factor: 25.606

3. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: J B A G Haanen; F Carbonnel; C Robert; K M Kerr; S Peters; J Larkin; K Jordan
Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976

4. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient.

Authors: Hiroaki Kanno; Kyoko Ishida; Wataru Yamada; Takashi Nishida; Nobumichi Takahashi; Kiyofumi Mochizuki; Yuki Mizuno; Kanako Matsuyama; Tomoko Takahashi; Mariko Seishima
Journal: J Infect Chemother Date: 2017-05-18 Impact factor: 2.211

5. Development of Vogt-Koyanagi-Harada Disease-like Uveitis during Treatment by Anti-programmed Death Ligand-1 Antibody for Non-small Cell Lung Cancer: A Case Report.

Authors: Shunichi Suwa; Ryo Tomita; Keiko Kataoka; Shinji Ueno
Journal: Ocul Immunol Inflamm Date: 2021-04-02 Impact factor: 3.070

Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity.

1. Choroidal Neovascularization in Multifocal Choroiditis after Dabrafenib and Trametinib.

Review 2. T cell exhaustion.

3. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

4. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient.

5. Development of Vogt-Koyanagi-Harada Disease-like Uveitis during Treatment by Anti-programmed Death Ligand-1 Antibody for Non-small Cell Lung Cancer: A Case Report.

6. Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes.

7. In vivo Confocal Microscopy in Differentiating Ipilimumab-Induced Anterior Uveitis from Metastatic Uveal Melanoma.

8. A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy.

9. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.

10. Ocular adverse events with immune checkpoint inhibitors.